Trial Profile
A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Balugrastim (Primary) ; Docetaxel; Doxorubicin; Pegfilgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 30 Sep 2014 New trial record